Gapping down
In reaction to earnings/guidance:
- PL -15.3%
Other news:
- ADGI -69.8% (reports reduction in in Vitro neutralizing activity of ADG20 against omicron SARS-CoV-2 variant)
- CABA -36.1% (reports top-line biologic activity data from two lowest dose cohorts in DesCAARTes trial in patients with mucosal pemphigus vulgaris)
- APTO -28.2% (HM43239 demonstrates durable clinical benefit)
- MESO -14.9% (provides update on Novartis (NVS) agreement)
- PRPL -7.9% (CEO stepping down names new CEO; expects rev adj. EBITDA at low end of previous guidance)
- TSVT -6.6% (Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting)
- GBIO -3.5% (provides update on preclinical studies for hemophilia A program)
- MX -2% (MX and Wise Road Capital mutually terminate acquisition agreement)
- CDTX -1.2% (announce positive topline results from the global phase 3 pivotal ReSTORE trial of Rezafungin for the treatment of candidemia and invasive candidiasis)
- BLU -1.1% (commences $175 mln stock offering) .
Analyst comments:
- DOCS -5.4% (downgraded to Underweight from Neutral at JP Morgan)
- DDOG -4.3% (downgraded to Neutral from Overweight at JP Morgan)
- RL -4.3% (downgraded to Sell from Buy at Goldman)
- ZS -4.2% (downgraded to Underweight from Neutral at JP Morgan)
- BIG -3.1% (downgraded to Sell from Neutral at Goldman)
- AKAM -2.7% (downgraded to Underweight from Neutral at JP Morgan)
- CDNS -2% (downgraded to Neutral from Overweight at JP Morgan)
- ADBE -1.9% (downgraded to Neutral from Overweight at JP Morgan)
- SPNS -1.3% (downgraded to Underweight from Neutral at JP Morgan)
- DOX -1% (downgraded to Neutral from Overweight at JP Morgan)